We are live on ! Find out more

Nkarta

NKTX

Market cap $209M

2.92 USD

+0.01

0.34%

At close Updated Sep 14, 4:00 PM EDT

Pre-market

After hours

2.67

-0.25

8.56%

1 day

0.34%

5 days

2.1%

1 month

25.32%

3 months

6.57%

6 months

28.07%

Year to date

56.15%

1 year

48.22%

5 years

-89.28%

10 years

-93.9%

About: Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

Employees: 106

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

Nkarta to Participate in September Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the following investor conferences: September 16, 2026 H.C.

Nkarta to Participate in September Investor Conferences

Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026

SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its selection for three scientific presentations at ACR Convergence 2026 being held November 6-11 in Orlando.

Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026

Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development

Paris, France and New York, USA , July 23, 2026 (GLOBE NEWSWIRE) -- Paris, France and New York, USA, July 23, 2026 – Cyllene Therapeutics (“Cyllene Tx”), the global leader in non-replicating HSV-1 (nrHSV-1) vector technology in neurology, today announced the appointment of Alyssa Levin to its Board of Directors, where she will also serve as Chair of the Audit Committee. The company has also strengthened its leadership team with two key additions. Clara Cambon-Thiebaud joins as Vice President, Regulatory Affairs, based in New York, and Céline Breda as Vice President, Chemistry Manufacturing and Controls (CMC). This leadership team expansion comes as Cyllene Tx advances its lead candidate, EG110A, towards late-stage clinical development for neurogenic bladder-related incontinence.

Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development

Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

At 2 p.m. ET on Tuesday, June 30th, Nkarta President Nadir Mahmood will take part in a fireside at the H.C. Wainwright Cell Therapy Virtual Conference.

Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights

Enrollment ongoing at 4 billion cell dose level (12 billion cells in 3-dose cycle) across all indications in Ntrust-1 and Ntrust-2 Regulatory agreement supports expansion into community-based settings with outpatient dosing to reduce patient burden Initial clinical data from Ntrust-1 and Ntrust-2 expected to be presented at a medical meeting in 2026 Cash balance of $266.7 million on March 31, 2026, including cash, cash equivalents and investments, expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today reported financial results for the first quarter ended March 31, 2026.

Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights

Zacks Investment Research

NKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune Program

Nkarta stock jumps after FDA backs protocol changes for ongoing NKX019 studies, enabling outpatient dosing and boosting study efficiency, patient access and commercial potential.

NKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune Program

Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers

SOUTH SAN FRANCISCO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on key changes to the ongoing Ntrust-1 and Ntrust-2 clinical trials. The protocol amendments are designed to alleviate the need for overnight stays and reduce the overall burden on patients, enabling outpatient administration of NKX019 – an investigational CAR-NK cell therapy – by community research centers and community rheumatologists.

Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers

Nkarta to Participate in Needham Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the 25th Annual Needham Virtual Healthcare Conference.

Nkarta to Participate in Needham Virtual Healthcare Conference

Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights

SOUTH SAN FRANCISCO, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today reported financial results for the fourth quarter and year ended December 31, 2025. “2025 was a year of strategic importance for Nkarta as we onboarded a clinical team with deep autoimmune experience, right-sized our workforce to be a responsible steward of investor capital, and continued to advance our CAR-NK cell therapy platform through dose escalation in the clinic,” said Paul J. Hastings, Chief Executive Officer of Nkarta. “Thoughtfully leveraging our safety data, we are now dosing patients at 4 billion cells in a three-dose cycle for a total of 12 billion cells as we look to maximize the depth and durability of B-cell depletion and clinical response, positioning us to unlock the full potential of NKX019 for people living with autoimmune disease.”

Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights

Nkarta to Participate in March Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the following investor conferences:

Nkarta to Participate in March Investor Conferences

See News Rankings

Price charts implemented using Lightweight Charts™